Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia.
about
The endocannabinoid system in normal and pathological brain ageingCannabinoids for the treatment of dementiaCannabinoids for the treatment of dementiaCannabinoids in health and diseaseThe endocannabinoid system as an emerging target of pharmacotherapyAlzheimer's disease; taking the edge off with cannabinoids?Natural Phytochemicals in the Treatment and Prevention of Dementia: An OverviewInvestigational drugs for treating agitation in persons with dementia.The endocannabinoid system as a target for the treatment of neurodegenerative disease.[¹²⁵I]SD-7015 reveals fine modalities of CB₁ cannabinoid receptor density in the prefrontal cortex during progression of Alzheimer's diseaseWIN 55,212-2, agonist of cannabinoid receptors, prevents amyloid β1-42 effects on astrocytes in primary culture.Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial.Nabilone for the Treatment of Dementia-Associated Sexual Disinhibition.Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia.Cannabinoids and Dementia: A Review of Clinical and Preclinical Data.Cannabinoid CB2 receptors in human brain inflammation.Cannabinoids:their role in pain and palliation.The endocannabinoid system in neuropathological states.The multiplicity of action of cannabinoids: implications for treating neurodegeneration.The role of phytochemicals in the treatment and prevention of dementia.Medicinal plants and dementia therapy: herbal hopes for brain aging?The therapeutic potential of the endocannabinoid system for Alzheimer's disease.The influence of cannabinoids on generic traits of neurodegeneration.Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic.Cannabinoids: new promising agents in the treatment of neurological diseases.Cannabinoids in late-onset Alzheimer's disease.New approaches in the design and development of cannabinoid receptor ligands: multifunctional and bivalent compounds.Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been ….Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease.Involvement of inflammation in Alzheimer's disease pathogenesis and therapeutic potential of anti-inflammatory agents.Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders.The Use of Cannabinoids in Treating Dementia.Effects of tetrahydrocannabinol on balance and gait in patients with dementia: A randomised controlled crossover trial.Increased motor activity in cycloid psychosis compared to schizophrenia.Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study.Review of the neurological benefits of phytocannabinoids.Cannabis Therapeutics and the Future of Neurology
P2860
Q22242668-CFABFD03-6845-47AB-A0A6-58DAAA3D4F0BQ24241582-9FC7DB08-C7FC-424F-BC07-5A254E1F19F7Q24242873-AEF44C24-1B44-4A6A-B703-D273E94DBCD8Q24633884-BC4852D6-D521-4DC1-BDCA-DCC5A5316949Q24648473-99BC59FB-7096-418A-8548-B0289E656053Q24681412-A31019DF-067B-488A-A7BC-A5BD42B6EFC1Q26750581-906DA1BD-C7AD-47D6-9EA5-DCC9C0E7213FQ30250076-AEE0896A-68D8-4398-A89F-64ADC310EDAEQ34098196-E18533F0-592B-4B5B-A2EC-616FBC597EAEQ34269852-C8FBC88F-11D9-4203-81AD-E148BC4362ECQ35601542-619C9B59-6FBA-4E1A-8618-D66CD0DF47A8Q35730949-B56FC118-685D-42E4-93A4-00C30101C07CQ35746640-8B2B528E-48C4-4148-BD7A-643141E518C7Q35781874-0966B401-E49A-4248-9BEF-01455B501517Q36155898-DA79A697-869E-4FE5-BBBC-BC8FC7D8E162Q36416377-EEDA8567-DC1B-4819-AC11-5CD6C9F23D97Q37010970-1BE2FC0E-9226-42A6-8D2D-74D84C065529Q37444824-B5238F98-F7DE-440E-9CA8-D0283ABF28BCQ37793366-ECC3ADB4-F7FE-45F7-9D6F-9DDD3768B913Q37884566-45349838-069C-4B53-BFF5-6EC637131854Q37954368-6A36B723-ED93-415C-92FA-28147B2DF95EQ37997020-9057C9C0-B588-4237-85AE-5A7B039150AEQ38156518-C8ECE10E-AE92-4F1E-93E4-2B2B4B29872EQ38196398-15E60C4C-8377-4EC8-BBBE-E7314460C6BCQ38269376-BE2F4B59-BBA0-4C18-94F2-33C7DA2C5559Q38383508-AAC36A25-798F-4D2E-82F6-14CEFFAFAB33Q38395251-078E1B13-9A60-4F99-920F-8EAA210056D9Q38503842-984179DB-0553-4233-AFAC-BF5F46C022E9Q38566169-AD3CAB8C-B736-4EC9-AB6B-21E58F5E58E7Q38569669-14CD6EDD-3B87-4601-A857-18B226EAB215Q38996589-EEC21C50-3CEC-435C-8421-144FF20E0E4AQ39385097-9CC4259C-D980-4F8D-BAD9-030ADC1E3803Q39395073-B26CF825-01A1-4FD3-A705-34F30827311CQ43891306-7BCFC4DE-727C-447D-A9D3-9946EF939B9CQ47899977-BFC3D121-FF20-42D1-A8FA-CE237C25FC44Q55439675-4785D2D7-9185-421F-B9D3-EE5CF51F420BQ58596177-BEB0B33D-3BE2-4E10-BC0E-86BFD6A8DD53
P2860
Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia.
@en
Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia.
@nl
type
label
Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia.
@en
Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia.
@nl
prefLabel
Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia.
@en
Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia.
@nl
P2093
P2860
P921
P1433
P1476
Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia.
@en
P2093
Dieter Kunz
Richard Mahlberg
Uta Eichmann
P2860
P2888
P304
P356
10.1007/S00213-006-0343-1
P577
2006-03-07T00:00:00Z